Shots: The P-II study involves assessing AKCEA-ANGPTL3-LRx (SC, 40-80mg) vs PBO in 105 patients with hypertriglyceridemia, T2D, and NAFLD for 6mos. The P-II study resulted in meeting its primary & […]readmore
Tags : AKCEA-ANGPTL3-L(Rx)
Shots: Akcea and Ionis to receive $250M, up to $1.3B as development, regulatory and commercial milestone with royalties on global sales of AKCEA-ANGPTL3-L(Rx) splitting equally b/w the companies. Akcea will […]readmore